8th Zurich Immuno-Oncology Symposium

The 8th Zurich Immuno-Oncology Symposium will bring together clinicians and scientists from across the field of cancer immunotherapy to deepen the understanding of cancer, the immune system and immunotherapy.


Grosser Hörsaal Path D22
University Hospital Zurich
Schmelzbergstrasse 12
8091 Zurich




9 am - 5 pm




This event will be held in English.

09.00 a.m. Welcome
Isabelle Schmitt-Opitz / Matthias Guckenberger, University Hospital Zurich
Session 1: Perioperative immunotherapy – Isabelle Schmitt-Opitz & Christian Gutschow
09.05 a.m. Immunotherapy for everyone? Mastering the challenges of perioperative immunotherapy for lung cancer
Brendon Stiles, Montefiore Health System, Albert Einstein College of Medicine, New York
09.30 a.m. ESOPEC and clinical trials on immunotherapy for colorectal cancer
Christiane Bruns, University Hospital Cologne
09.55 a.m. Side effects of IT in the perioperative area
Jordi Remon Masip, Gustave Roussy, Paris
10.20 a.m. Coffee break
Session 2: Oncology – Anja Lorch & Ralph Fritsch
10.45 a.m. The microbiome to overcome resistance to cancer immunotherapies
Michael Scharl, University Hospital Zurich
11.10 a.m. Renal cell cancer: Immuno-oncology 2024 and beyond
Manuela Schmidinger, Medical University of Vienna
11.35 a.m. Targeting the immune desert – immunotherapy for pancreatic cancer
Jens Siveke, University Hospital Essen
12.00 p.m. New immunotherapy approaches for melanoma
Reinhard Dummer, University Hospital Zurich
12.25 p.m. Lunch
1.10 p.m. Welcome Director of University Medicine Zurich
Beatrice Beck-Schimmer
Session 3: Optimal combination of radiotherapy and immunotherapy – what’s new?
Panagiotis Balermpas & Matthias Guckenberger
1.15 p.m. Keynote lecture: Radiotherapy-immunotherapy combinations, current and future perspectives
Silvia C. Formenti, Weill Cornell, New York
1.40 p.m. Challenges on the way to personalized radio-immunotherapy combination treatments
Eric Deutsch, Gustave Roussy, Paris
2.05 p.m. Clinical implementation of the combination of immuno-radiotherapy using the example of head and neck cancer: How can synergies between the treatment modalities be optimized?
Kevin Harrington, Royal Marsden, United Kingdom
2.30 p.m. Lymphatic sparing improves the response to radiotherapy
Martin Pruschy, University Hospital Zurich
2.55 p.m. Coffee break
Session 4: Patrick Roth & Markus G. Manz
3.30 p.m. Anti-angiogenic immunotherapy
Arjan Griffioen, Amsterdam UMC
3.55 p.m. Overcoming exhaustion in cancer immunotherapy
Alfred Zippelius, University of Basel
4.20 p.m. Neurological complications of cancer immunotherapy
Antoine Carpentier, Paris
4.45 p.m. Conclusion
Panagiotis Balermpas / Markus G. Manz, University Hospital Zurich